Securitas AB Interim Report Q1 2026 | January–March

The company reported January–March 2026 sales of MSEK 36,211, down from MSEK 39,606, while operating income before amortization slipped to MSEK 2,459 from MSEK 2,525. Margins improved, with operating margin at 6.8% versus 6.4% and adjusted operating margin at 7.0% versus 6.7%, while adjusted organic sales growth was 2%. EPS rose to SEK 2.80 from SEK 2.29, but the release is mixed overall given lower sales and modestly better profitability.

Analysis

This is a quality-over-quantity print: the company is defending margin despite flat underlying top-line momentum, which usually matters more for valuation than the headline sales miss. The hidden positive is mix/price discipline in the technology-and-solutions bucket, implying management is prioritizing returns on capital over chasing low-margin volume; that tends to support earnings durability even when demand is choppy. The market should also read the adjusted margin expansion as evidence that the business is still extracting productivity gains from the cost base, which can cushion downside if macro weakens further.

The second-order issue is that divestiture-related IACs are doing two jobs at once: they boost near-term reported earnings optics while masking the true cash conversion trajectory. If the assets sold were subscale or low-return, this is constructive for long-term ROIC; if they were a hedge against cyclicality, then the company is effectively becoming more exposed to the underlying end-market slowdown over the next 2-3 quarters. That makes the next catalyst less about the current quarter and more about whether management can prove that the post-divestiture portfolio can grow organically without margin leakage.

For competitors, this reads as a warning shot rather than a victory lap. A firm that can hold margins on stagnant sales is usually gaining pricing power or buying back efficiency through restructuring, which pressures peers still carrying heavier fixed-cost leverage. The main risk is that this is the late-cycle part of the earnings bridge: if demand does not reaccelerate within 1-2 quarters, incremental operating leverage becomes negative and the current margin resilience can reverse quickly.

The contrarian view is that investors may be underestimating the earnings quality improvement embedded in the portfolio reshaping. Flat organic sales often get punished, but when adjusted margins improve and EPS holds up, the market can rerate the business as a cleaner compounder rather than a cyclical operator. The key question is whether this is the start of a more efficient earnings stream or just a temporary benefit from pruning weaker assets.

Key Decisions for Investors

• If liquid in the local market, buy the stock on any 3-5% post-earnings pullback and target a 1-2 quarter hold; the risk/reward favors upside if management confirms margin retention in the next print.
• Add to a relative-value long versus a lower-margin peer in the same industrial/technology services complex; the spread should work over the next 60-90 days if pricing discipline holds.
• Avoid chasing the stock after an earnings pop unless management guides to renewed organic growth; the current setup is more a margin-defense story than an acceleration story.
• If you own a basket of restructuring beneficiaries, pair long this name against a more levered cyclical competitor to capture the quality premium, with downside bounded by the margin floor.
• Set a catalyst watch for the next quarter's organic growth and cash flow conversion; if either slips, fade the move because the market will likely reclassify this as a one-off efficiency gain rather than a structural improvement.